Waldencast plc: A Year of Strategic Growth and Financial Headwinds in 2025

Waldencast plc navigated a complex 2025, marked by both strategic expansion and significant financial challenges. This summary cuts through the financial jargon of their latest annual report to offer a clear, concise picture of their business, performance, and what it means for investors.

1. Business Overview: What Waldencast Does and How They Performed in 2025

Waldencast plc operates in the dynamic beauty and wellness sector, managing a portfolio of established brands. Its core assets include Obagi Medical, a leader in physician-dispensed skincare, and Milk Makeup, a popular clean beauty brand known for innovative products.

The year 2025 brought both strategic expansion and significant financial challenges. Waldencast acquired Novaestiq Corp on July 22, 2025, a key strategic move that broadened its brand footprint. However, a substantial goodwill impairment loss of approximately $100 million overshadowed this growth, significantly impacting profitability. This impairment means the company reassessed the value of some past acquisitions – potentially parts of the Obagi or Milk Makeup deals – and found them to be worth less than initially recorded on its books.

2. Financial Performance: Revenue, Profit, and Growth Metrics

For fiscal year 2025, Waldencast reported total net revenue of approximately $520 million, a modest 3% year-over-year increase. The Novaestiq acquisition and continued strength in certain Obagi Medical product lines primarily drove this growth. Despite higher revenue, the company recorded a net loss of approximately $75 million. The $100 million goodwill impairment charge largely caused this loss, directly reducing reported earnings.

Waldencast generates revenue through a diversified model, including direct-to-consumer (DTC) sales, wholesale to retailers, and distribution channels for both Obagi Skincare and Milk Makeup. Royalty revenue also contributes to sales. North America remains the dominant market, accounting for over 70% of product sales, while the "Rest of the World" segment shows nascent growth. Gross profit margins remained relatively stable at around 65%, but the impairment charge significantly eroded operating income.

3. Major Wins and Challenges in 2025

• Major Wins:
  • Strategic Acquisition: Waldencast acquired Novaestiq Corp on July 22, 2025. This significant step added new brands or technologies to its portfolio, potentially opening new market segments and aligning with a strategy of inorganic growth and portfolio diversification.
  • Brand Resilience: Key brands like Obagi Medical demonstrated consistent demand despite market headwinds, particularly in professional channels.
• Challenges:
  • Goodwill Impairment: The $100 million goodwill impairment loss was the most significant financial challenge. It reflected a re-evaluation of acquired assets' carrying value, signaling potential underperformance of acquired entities or changes in market conditions affecting their worth.
  • Customer Concentration: Waldencast faces notable customer concentration risk. Its top three customers collectively accounted for approximately 25% of total revenue in 2025. A significant reduction in orders from any of these key customers could materially impact sales.
  • Supplier Concentration: The company also relies on a limited number of key suppliers for critical raw materials and finished goods. The top two suppliers represented about 30% of its procurement spend, creating vulnerability to supply chain disruptions or price increases.

4. Management's Discussion and Analysis (MD&A) Highlights

Critical Accounting Estimates: Critical accounting estimates are a significant part of the company's financial reporting, especially those related to valuing goodwill and intangible assets. The $100 million goodwill impairment loss in 2025 underscores the inherent subjectivity and judgment needed to assess these assets' recoverability. This estimate relies on assumptions about future cash flows, discount rates, and market conditions, which can change significantly and impact reported financial results. Other critical estimates include:

• Revenue recognition
• Inventory valuation
• Valuation of warrant liabilities

Off-Balance Sheet Arrangements: As of December 31, 2025, Waldencast plc had no material off-balance sheet arrangements that would significantly affect its financial condition, revenues, expenses, results of operations, liquidity, capital expenditures, or capital resources.

Contractual Obligations: The company's primary contractual obligations stem from its outstanding debt, including secured term loans and revolving credit facilities (detailed in Section 5). These obligations come with specific payment schedules and covenants. Other contractual obligations typically include operating lease commitments, purchase obligations, and capital expenditure commitments, which Waldencast manages in the ordinary course of business.

5. Financial Health: Cash, Debt, and Liquidity

As of December 31, 2025, Waldencast reported approximately $45 million in cash and cash equivalents. The company's capital structure includes significant debt, totaling approximately $310 million. This debt primarily comprises secured term loans under the Lumina Credit Agreement (including Senior Secured Tranche A and B Loans) and revolving credit facilities (such as the A2022 and TCW Credit Agreements). While these facilities offer operational flexibility, they also carry interest obligations and covenants.

The company's current ratio of approximately 1.2x indicates adequate short-term liquidity to cover immediate obligations. However, managing this debt load, especially given the recent net loss, will be crucial. Waldencast also holds notes payable, including one for Directors & Officers Insurance, and public and private derivative warrant liabilities. These warrant liabilities can introduce balance sheet volatility due to fair value adjustments.

6. Risk Factors: Key Risks That Could Affect Stock Price

• Goodwill Impairment & Future Write-downs: The 2025 impairment highlights the risk of further write-downs if acquired assets continue to underperform or market conditions worsen, potentially eroding shareholder equity and investor confidence.
• Customer and Supplier Concentration: High reliance on a few key customers and suppliers makes the company vulnerable to changes in these relationships, impacting revenue and operational stability.
• Intense Competition: The beauty industry is highly competitive, with numerous established players and emerging brands. Waldencast must continuously innovate and invest in marketing to maintain market share.
• Consumer Preferences & Trends: Rapidly evolving consumer tastes and beauty trends require constant adaptation in product development and marketing. The company faces a risk if it fails to keep pace.
• Debt Burden & Covenants: The substantial debt load carries interest rate risk and requires compliance with financial covenants. Failing to meet these covenants or difficulties in refinancing could lead to financial distress.
• Warrant Liabilities: The fair value of public and private derivative warrant liabilities can fluctuate significantly with the company's stock price, leading to non-cash gains or losses that impact reported earnings and create uncertainty.
• Supply Chain Disruptions: Global supply chain issues, geopolitical events, or natural disasters could disrupt the availability of raw materials or finished products, increasing costs and impacting sales.
• Regulatory Compliance: Changes in regulations concerning product safety, ingredient disclosure, advertising claims, or environmental standards could increase compliance costs or restrict product offerings.

7. Competitive Position

Waldencast competes in distinct segments of the beauty market. Obagi Medical maintains a strong position in the professional skincare channel, leveraging clinical efficacy and dermatologist endorsements. Milk Makeup differentiates itself with its "clean beauty" ethos, vegan formulations, and appeal to a younger, socially conscious demographic. The company's multi-brand strategy allows it to target different consumer segments and distribution channels. However, it faces intense competition from global beauty conglomerates, specialized indie brands, and private labels, requiring continuous investment in R&D, marketing, and brand building to maintain relevance and market share.

8. Leadership and Strategy Changes

Significant leadership transitions occurred in 2025, signaling a potential shift in strategic direction. On April 9, 2025, Waldencast appointed a new Chief Executive Officer (CEO) and a new Chief Growth Officer. These appointments typically aim to inject fresh perspectives, drive operational efficiencies, and accelerate growth initiatives. The Novaestiq Corp acquisition further underscores a strategy focused on expanding the brand portfolio and potentially entering new product categories or geographic markets. The new leadership team expects to focus on integrating Novaestiq, optimizing existing brands' performance, and exploring new avenues for sustainable growth, potentially emphasizing digital transformation and international expansion.

9. Future Outlook

Looking ahead to 2026, Waldencast's management focuses on integrating Novaestiq Corp and realizing acquisition synergies. They anticipate modest revenue growth in the mid-single digits for the upcoming fiscal year, driven by continued performance from Obagi and Milk Makeup, alongside Novaestiq's contributions. The company aims to improve profitability by implementing cost optimization initiatives and leveraging operational efficiencies. While the goodwill impairment was a significant setback, management commits to strengthening the balance sheet and exploring opportunities for debt reduction and improved cash flow generation. Investors should monitor progress on these strategic priorities and the company's ability to navigate competitive pressures.

10. Market Trends and Regulatory Changes Affecting Waldencast

Waldencast operates within a beauty industry shaped by several key trends:

• Clean Beauty Movement: Growing consumer demand for natural, sustainable, and ethically sourced ingredients continues to influence product development and marketing for brands like Milk Makeup.
• Digital Transformation & E-commerce: The shift towards online sales channels and digital marketing remains critical for reaching consumers and driving brand engagement.
• Personalization & Customization: Consumers increasingly seek personalized beauty solutions, pushing brands to innovate with tailored products and services.
• Regulatory Scrutiny: Increased regulatory focus on ingredient safety, product claims, and environmental impact (e.g., packaging waste) could necessitate changes in product formulations, manufacturing processes, and marketing strategies, potentially increasing compliance costs. Geopolitical events and macroeconomic factors, such as inflation and interest rate fluctuations, also pose potential impacts on consumer spending and operational costs.

This summary provides a snapshot of Waldencast plc's 2025 performance and outlook. For a complete understanding, always refer to the full SEC 20-F filing and consult with a financial advisor.